Please sign in to follow a disease.
Polaris Group
Clinical trials sponsored by Polaris Group, explained in plain language.
Biopharmaceutical company developing cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug targets liver cancer by starving tumors of arginine
Disease control Recruiting nowThis study tests a drug called ADI-PEG 20 against a placebo in 300 people with advanced liver cancer that cannot be removed by surgery. Only people with high levels of the amino acid arginine in their blood can join. The goal is to see if the drug helps them live longer by breaki…
Phase 3 • Sponsor: Polaris Group • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug aims to melt liver fat in NASH patients
Disease control Recruiting nowThis study tests a drug called ADI-PEG 20 against a placebo in 60 adults with nonalcoholic steatohepatitis (NASH), a type of fatty liver disease. Participants receive injections over 24 weeks, and doctors measure changes in liver fat using MRI. The goal is to see if the drug can …
Phase 2 • Sponsor: Polaris Group • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC